(DEBS), company issued guidance for (Jan) quarter, ups EPS forecast to $1.68-1.73, up from previous guidance of $1.65-1.70 vs. $1.70 Reuters Estimates consensus.
(DECK), company issued upside guidance for (Dec) quater, sees EPS to exceed $0.64 vs. $0.64 Reuters Estimates consensus; sees Q4 revs to exceed $75 mln vs. $74.89 mln consensus. It issues in-line guidance for 2006, reaffirms $2.00-2.15 vs. $2.05 consensus; sees 2006 revs of $255-265 m vs. $254.10 mln consensus.
(CBOU), company issued 2006 EPS of ($0.10)-(0.20) vs. $0.01 consensus. It also announces that preliminary full-year 2005 net sales increased approx 24%. Comparable same store sales increased 2% for the thirteen weeks ended Jan 1, 2006 compared with the same thirteen weeks in the prior year. For the full-year, comparable same store sales were up 6% compared to the same 52 weeks in the prior year.
(SLXP) new updates: "XIFAXAN(R) Trials Initiated in C. difficile-Associated Diarrhea, Irritable Bowel Syndrome and Hepatic Encephalopathy COLAZAL(R) 1100 mg Tablet Formulation Trial Initiated in Ulcerative Colitis"
(DD), DuPont guides Q4 EPS below consensus.
No comments:
Post a Comment